Prophylactic Recombinant Human Thrombopoietin Prevents Cancer Therapy-Induced Thrombocytopenia During Concurrent Chemoradiation Therapy in Limited-Stage Small Cell Lung Cancer: A Prospective, Multicenter, Phase II Clinical Trial.

In 30 seconds

This prospective, multicenter, phase II trial assessed prophylactic recombinant human thrombopoietin (rhTPO) during concurrent chemoradiation in patients with limited-stage small cell lung cancer. Among 56 patients treated at 14 Chinese centers, cancer therapy-induced thrombocytopenia occurred in 33.9% (19/56), including grade 3 events in 8.9% (5/56), with no grade 4-5 events. Of those who developed thrombocytopenia, 78.9% (15/19) recovered to platelet counts ≥100 × 10 9 /L during rhTPO treatment. No patient required platelet transfusion or had radiation therapy interrupted. The authors conclude that rhTPO may help maintain platelet counts and warrants further study.

Key findings

• CTIT occurred in 33.9% (19/56); 8.9% (5/56) had grade 3 events, and none had grade 4-5 events.
• Platelet counts recovered to ≥100 × 10 9 /L during rhTPO treatment in 78.9% of patients with CTIT (15/19); median recovery time was 8 days (95% CI, 6-14).
• No patients required platelet transfusions or experienced radiation therapy interruptions; one patient required chemotherapy dose reduction.
• Baseline platelet count <150 × 10 9 /L was associated with CTIT (odds ratio, 4.26; 95% CI, 1.08-16.78; P = .038).

Why it matters

Thrombocytopenia during concurrent chemoradiation can disrupt treatment delivery. These findings suggest prophylactic rhTPO may support platelet recovery in this setting, while also identifying low baseline platelet count as a risk marker. The results provide a rationale for further evaluation, but the trial does not establish comparative efficacy against no prophylaxis or another strategy.

What to keep in mind

The phase II trial included 56 patients and had no comparator group, limiting conclusions about rhTPO's efficacy relative to usual care.